Sunday 18 October 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.
2.42
0.06
−2.42%
Follow GNLX
Genelux Corporation (GNLX) P/E ratio
Genelux Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2024 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ENGN enGene Therapeutics Inc compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| TNXP Tonix Pharmaceuticals Holding Corp. compare | n/m |
| FHTX Foghorn Therapeutics Inc. compare | n/m |
| SEER Seer, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| VTVT vTv Therapeutics Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| GNLX Genelux Corporation | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)